Status:

COMPLETED

A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma

Lead Sponsor:

Sumitomo Pharma America, Inc.

Conditions:

Asthma

Eligibility:

All Genders

12+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to compare the safety and tolerability of levalbuterol HFA metered dose inhaler (MDI) versus racemic albuterol HFA MDI.

Detailed Description

A randomized, modified-blind active-controlled multicenter, two-way crossover study of levalbuterol compared to racemic albuterol (using a spacer) in subjects 12 years of age and older with asthma. Th...

Eligibility Criteria

Inclusion

  • Subject, male or female, must be at least 12 years of age at the time of consent.
  • Female subjects 12-60 years of age inclusive must have a negative serum pregnancy test at study start.
  • Women of child bearing potential must be using an acceptable method of birth control throughout the study.
  • Subject must have a documented diagnosis of asthma for a minimum of 6 months prior to study start.
  • Subject must be in good health with the exception of their reversible airways disease and not suffering from any chronic condition that might affect their respiratory function.
  • Subject must have a chest X-ray or had one within 12 months prior to randomization.
  • Subject must be able to complete the diary cards and medical event calendars reliably on a daily basis, understand dosing instructions and be able to demonstrate good MDI administration technique. Any minor subject who is not able to do this must have a parent/legal guardian who can assist them during the study with these activities.

Exclusion

  • Female subject who is pregnant or lactating.
  • Subject who has participated in an investigational drug study within 30 days prior to study start, or who is currently participating in another clinical trial.
  • Subject whose schedule prevents him or her from starting study visits before 9 AM.
  • Subject who has travel commitments during the study that would interfere with trial measurements or compliance or both.
  • Subject who has a history of hospitalization for asthma within 4 weeks prior to study start, or who is scheduled for in-patient hospitalization, including elective surgery during the course of the trial
  • Subject with a known sensitivity to levalbuterol or racemic albuterol, or any of the excipients contained in any of these formulations.
  • Subject using any prescription drug with which albuterol sulfate administration is contraindicated.
  • Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start.
  • Subject with a history of cancer (exception: basal cell carcinoma in remission).
  • Subject with hyperthyroidism, diabetes, hypertension, cardiac diseases or seizure disorders.
  • Subject with a history of substance abuse or drug abuse within 12 months preceding study start.
  • Subject with greater than 10 pack year history of cigarette smoking or use of any tobacco products within 6 months of study start.
  • Subject with a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis.
  • Subject who has suffered from a clinically significant upper or lower respiratory tract infection in the 3 weeks prior to study start.
  • Subject with unstable asthma; or who have had a change in asthma therapy; or a visit to the Emergency Department or hospital for worsening asthma within 4 weeks.
  • Subject who is a staff member or relative of a staff member.

Key Trial Info

Start Date :

October 1 2002

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2003

Estimated Enrollment :

32 Patients enrolled

Trial Details

Trial ID

NCT00684827

Start Date

October 1 2002

End Date

February 1 2003

Last Update

February 22 2012

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Encinitas, California, United States

2

Los Angeles, California, United States

3

North Dartmouth, Massachusetts, United States

4

St Louis, Missouri, United States